In one study testing the hypothesis that CD200 drives the expansion and activity of MDSCs in pancreatic ductal adenocarcinoma (PDAC), an anti-CD200 antibody used to block CD200/CD200R signaling was shown to inhibit PDAC tumor growth in murine models and significantly decrease the levels of tumor infiltrating MDSCs [61]. This evidence concerns the gene CD200 and pancreatic ductal adenocarcinoma.